395 related articles for article (PubMed ID: 24307220)
1. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Wilson RJ; Keith MS; Preston P; Copley JB
Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
[TBL] [Abstract][Full Text] [Related]
2. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Keith MS; Wilson RJ; Preston P; Copley JB
Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
[TBL] [Abstract][Full Text] [Related]
6. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
[TBL] [Abstract][Full Text] [Related]
7. Study of prolonged administration of lanthanum carbonate in dialysis patients.
Gotoh J; Kukita K; Tsuchihashi S; Hattori M; Iida J; Horie T; Onodera K; Furui H; Tamaki T; Meguro J; Yonekawa M; Kawamura A
Ther Apher Dial; 2013 Apr; 17 Suppl 1():9-14. PubMed ID: 23586507
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
[TBL] [Abstract][Full Text] [Related]
10. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
[TBL] [Abstract][Full Text] [Related]
11. Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.
Kasai S; Sato K; Murata Y; Kinoshita Y
Ther Apher Dial; 2012 Aug; 16(4):341-9. PubMed ID: 22817122
[TBL] [Abstract][Full Text] [Related]
12. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Vemuri N; Michelis MF; Matalon A
BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
14. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
[TBL] [Abstract][Full Text] [Related]
15. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
16. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Noto L
J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
Arenas MD; Rebollo P; Malek T; Moledous A; Gil MT; Alvarez-Ude F; Morales A; Cotilla E
J Nephrol; 2010; 23(6):683-92. PubMed ID: 20540040
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lanthanum carbonate in German patients on dialysis.
Dellanna F; Reichel H; Seibt F
Clin Nephrol; 2012 Nov; 78(5):382-90. PubMed ID: 22948119
[TBL] [Abstract][Full Text] [Related]
19. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
